Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era

[1]  J. Cerhan,et al.  Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era , 2016, British journal of haematology.

[2]  R. Stephens,et al.  Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. , 2014, The Lancet. Oncology.

[3]  J. Cerhan,et al.  Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Kimby,et al.  ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[6]  S. Montoto,et al.  Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Salles,et al.  Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Giovanni Martinelli,et al.  Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Jaffe,et al.  The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. , 2009, Hematology. American Society of Hematology. Education Program.

[10]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[11]  R. Advani,et al.  Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Maclennan,et al.  Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.

[13]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[14]  G. Giaccone,et al.  An update on European randomized studies in non-small cell lung cancer. , 1998, Seminars in oncology.

[15]  J. Rossi,et al.  Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Tilly,et al.  Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Horning.  Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.

[18]  E. Jaffe,et al.  The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. , 1988, Seminars in hematology.

[19]  S. Horning,et al.  The natural history of initially untreated low-grade non-Hodgkin's lymphomas. , 1984, The New England journal of medicine.